According to an analysis performed at the University of Hong Kong, offering patients with diabetes free screening for diabetic retinopathy is the most cost-effective screening approach for identifying patients with signs of that complication.Results from the analysis, which used a cost/benefit threshold of approximately US$13,000 per quality-adjusted life-year (QALY) gained, were reported here at the World Ophthalmology Congress 2012.To see more details visit,www.medscape.com
